NCT04839471View on ClinicalTrials.gov

BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

July 24, 2023

Study Completion Date

June 19, 2024

Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
DRUG

BI-754091 plus afatinib

Eligible patients will receive BI-754091 240 mg on D1, afatinib 30 mg/day on day 1 to 21 in a 3-week cycle.

Trial Locations (4)

Unknown

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

China Medical University Hospital, Taichung

National Cheng-Kung University Hospital, Tainan City

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

China Medical University Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER

NCT04839471 - BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study) | Biotech Hunter | Biotech Hunter